MDPI Antibiotics Published a Review Paper Synthesizing the Dual Antimicrobial-and-Anticancer Activity of Frog-Skin-Derived Peptides Including Dermaseptins, Temporins, and Brevinins, Documenting Their Selective Membrane-Disruption Mechanism Against Both Bacterial Pathogens (Broad-Spectrum Cationic Amphipathic Activity Against Multidrug-Resistant Bacteria) and Cancer Cells (Selective Electrostatic Interactions With Negatively Charged Malignant Cell Membranes Producing Membrane Disruption Plus Apoptosis or Necrosis Induction); The Frog-Skin AMP Family Represents One of the Most-Studied Natural Sources of Bioactive Antimicrobial Peptides With Cross-Category Therapeutic Potential Extending the Broader Anticancer AMP Research Trajectory Anchored by the Nature aMPC16-CA50 Membranolytic Peptide Study and the Frontiers in Medicine 2026 Comprehensive Review
MDPI Antibiotics published a review paper synthesizing the dual antimicrobial-and-anticancer activity of frog-skin-derived peptides. The paper covers three main families: dermaseptins (originally isolated from Phyllomedusa frogs and studied since the 1990s), temporins (small linear peptides typically 10-14 amino acids from Rana temporaria and related species), and brevinins (larger amphipathic peptides from Rana and Sylvirana genera). Mechanism synthesis: the peptides disrupt microbial membranes through broad-spectrum cationic amphipathic activity against multidrug-resistant bacteria while also selectively targeting cancer cells through electrostatic interactions with the negatively charged phospholipid outer leaflets that are characteristic of many cancer cell membranes. Cancer-cell membrane disruption is followed by apoptosis or necrosis induction in ways that differ from traditional cytotoxic chemotherapy. The frog-skin AMP family represents one of the most-studied natural sources of bioactive antimicrobial peptides with cross-category therapeutic potential. The review extends the broader anticancer AMP research trajectory anchored by the August 7, 2026 Nature paper on the aMPC16-CA50 synthetic acid-responsive membranolytic peptide that induces immunogenic cell death and the Frontiers in Medicine 2026 comprehensive review on AMPs as cancer therapeutics and vaccine adjuvants. Clinical translation challenges remain (high toxicity at effective anticancer doses, poor systemic stability, limited cellular penetration, and costly synthesis) but the mechanism-of-action diversity across dermaseptins, temporins, and brevinins provides a broad pipeline for continued preclinical and early-clinical work.